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Background: Argininosuccinate synthetase (ASS) participates in urea, nitric oxide and arginine production. Besides
transcriptional regulation, a post-transcriptional regulation affecting nuclear precursor RNA stability has been reported.
To study whether such post-transcriptional regulation underlines particular temporal and spatial ASS expression,
and to investigate how human ASS gene behaves in a mouse background, a transgenic mouse system using a
modified bacterial artificial chromosome carrying the human ASS gene tagged with EGFP was employed.
Results: Two lines of ASS-EGFP transgenic mice were generated: one with EGFP under transcriptional control
similar to that of the endogenous ASS gene, another with EGFP under both transcriptional and post-
transcriptional regulation as that of the endogenous ASS mRNA. EGFP expression in the liver, the organ for urea
production, and in the intestine and kidney that are responsible for arginine biosynthesis, was examined. Organs
taken from embryos E14.5 stage to young adult were examined under a fluorescence microscope either directly
or after cryosectioning. The levels of EGFP and endogenous mouse Ass mRNAs were also quantified by S1 nuclease
mapping. EGFP fluorescence and EGFP mRNA levels in both the liver and kidney were found to increase progressively
from embryonic stage toward birth. In contrast, EGFP expression in the intestine was higher in neonates and started to
decline at about 3 weeks after birth. Comparison between the EGFP profiles of the two transgenic lines indicated the
developmental and tissue-specific regulation was mainly controlled at the transcriptional level. The ASS transgene
was of human origin. EGFP expression in the liver followed essentially the mouse Ass pattern as evidenced by
zonation distribution of fluorescence and the level of EGFP mRNA at birth. However, in the small intestine, Ass
mRNA level declined sharply at 3 week of age, and yet substantial EGFP mRNA was still detectable at this stage.
Thus, the time course of EGFP expression in the transgenic mice resembled that of the human ASS gene.
Conclusions: We demonstrate that the transgenic mouse system reported here has the merit of sensitivity and
direct visualization advantage, and is ideal for annotating temporal and spatial expression profiles and the
regulation mode of the ASS gene.
Keywords: Argininosuccinate synthetase, Transgenic mouse, Bacterial artificial chromosome, Green fluorescence
protein, Developmental regulation, Tissue-specific regulation, Post-transcriptional regulationBackground
Argininosuccinate synthetase (ASS; EC 6.3.4.5) is an en-
zyme that functions in the catalysis of the conversion of
citrulline and aspartate to argininosuccinate, which is
further converted to arginine by argininosuccinate lyase
[1,2]. ASS catalyzes the rate-limiting step in arginine
biosynthesis. Arginine plays a role in the synthesis of* Correspondence: su31659@gmail.com
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unless otherwise stated.urea, nitric oxide (NO), polyamines, proline, glutamate,
creatine and agmatine [3]. Thus, ASS participates in
fine-tuning production of NO and others to maintain
cellular homeostasis in response to cellular and environ-
mental stimuli. Conceivably, ASS, one of the key en-
zymes involving in arginine metabolism, is subjected to
various mechanisms of regulation in both physiological
and disease states.
Hormones, such as glucocorticoid, glucagon and insu-
lin, are major regulators of the expression of urea cycle
enzymes in the liver [1,2]. We have previously identified
that the cAMP response element (CRE) located at abouttd. This is an Open Access article distributed under the terms of the Creative
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man ASS gene is most likely the target site of the CRE-
binding protein (CREB) to mediate glucagon action [4].
However, the mechanism by which glucocorticoid and
insulin act on ASS expression remains unknown. On the
other hand, ASS expression in non-hepatic cells were
shown to be induced by interleukin-1β through NF-κB
activation acting at a putative NF-κB binding site at the
ASS promoter [5]. Moreover, the proximal promoter of
the ASS gene was shown to contain an E-box recognized
by c-Myc and HIF-1α, and a GC-box targeted by Sp4
where ASS expression involves interactions between the
positive transcriptional factors c-Myc and Sp4 and the
negative factor HIF-1α [6]. In addition to regulation at
transcription initiation, we have also identified a novel
post-transcriptional event affecting ASS nuclear precur-
sor RNA stability in the canavanine-resistant variants of
a human squamous cell carcinoma line, RPMI 2650 [7].
These variants express 200-fold increased levels of ASS
mRNA as compared to the parental cells [8]. The
canavanine-resistant variants have increased ASS activ-
ities, and are presumably resistant to canavanine be-
cause of increased conversion of citrulline to arginine.
The post-transcriptional regulation identified in the
canavanine-resistant variants may have physiological
relevance since it has the advantage of being faster than
transcriptional regulation. One would image that under
particular circumstances such as inflammation, cells
may employ such a mode of regulation to produce
higher levels of ASS mRNA to meet the need for NO
production. It is worth noting that similar canavanine-
resistant cells have been isolated from lymphoblasts [9].
To identify cellular targets or events that employ such
regulation, a suitable ASS expression profiling system is
essential. To this end, we took BAC (bacterial artificial
chromosome) containing the entire human ASS structural
gene of 57 kb flanked by 97 kb and 16 kb of genomic se-
quences at its 5′- and 3′-ends, respectively, as a starting
construct to knock-in the EGFP (enhanced green fluores-
cence protein) coding sequence. Two types of ASS-EGFP
transgene were constructed (Figure 1). One is designated
as a transcription reporter, Tg(ASS-Ex3-EGFP). In such a
construct, EGFP is knocked in at a position of authentic
initiation codon residing in exon 3 of the ASS gene where
EGFP transcription termination is regulated by a SV40
poly(A) signal. The EGFP level in this construct would,
therefore, essentially reflect the transcription activities of
the ASS gene. Another one is designated as a transcrip-
tion/post-transcription couple reporter, Tg(ASS-Ex16-
EGFP), in which the EGFP knock-in sequence also con-
tains the sequence of the internal ribosome entry site
(IRES), and the hybrid sequence is inserted into exon 16,
the terminal exon of the ASS gene, at site between the
ASS stop codon and the polyA signal. In such aconfiguration, the human ASS and the EGFP genes are
transcribed as a bicistronic RNA, and EGFP, the down-
stream cistron, is translated by the IRES mechanism. Thus,
EGFP activity expressed from such a transgene is subjected
to both transcriptional and post-transcriptional regulation
as that of the endogenous ASS mRNA. Using transgenic
mice carrying these ASS-EGFP reporters, we show here
that location of EGFP in the liver and kidney, the major
organ of ASS production, is essentially mimic that of the
endogenous Ass gene, suggesting sufficient regulatory
element(s) is included in the ASS-EGFP transgene.
To obtain the temporal and spatial expression profiles
of ASS transgene, major efforts in this study are to estab-
lish the developmental expression pattern of ASS-EGFP
in the liver, the organ for urea production, and in the in-
testine and kidney where arginine biosynthesis occurs.
By comparing the expression patterns between Tg(ASS-
Ex3-EGFP) that are carrying the transcription reporter
and Tg(ASS-Ex16-EGFP) that are carrying the transcrip-
tion/post-transcription couple reporter, we aim to de-
duce at which level the expression control acts during
development. Moreover, the ASS transgene is of human
origin. It would be of interest to know how a human
gene behaved in the mouse genetic background.
Methods
Animals
Mice were housed in a specific pathogen-free (SPF)
area of the animal room in the Taipei Veterans General
Hospital and were maintained according to protocols
approved by the Animal Care and Use Committee of
Taipei Veterans General Hospital. The male transgenic
mice of the FVB/N strain carrying the ASS-EGFP trans-
gene, i.e., Tg(ASS-Ex3-EGFP) or Tg(ASS-Ex16-EGFP),
were mated with wild-type FVB/N female where partur-
ition occurred on day 17.5 or 18.5 after conception.
Progenies carrying EGFP transgene were identified by
visualization of fluorescence of two-week old litter-
mates by a portable fluorescence detection system. The
transgenic mouse lines Tg(ASS-Ex3-EGFP)Tsu and Tg
(ASS-Ex16-EGFP)Tsu have been deposited in National
Laboratory Animal Center, Taiwan, and are available for
researchers on requests.
Histological study
Histological study was performed following standard pro-
tocols [10]. In brief, mice were sacrificed by anesthetized
with CO2 and tissue collected was fixed in 4% buffered
paraformaldehyde. For frozen section, after dehydration in
graded sucrose solution, tissue was embedded in OCT
(Optimal Cutting Temperature) compound (Tissue Tec,
Sakara, Torrance, CA). Serial sections were performed
with Leica cryostat (Leica Biosystems, Wetzlar, Germany)
and mounted onto slides to examine EGFP expression by
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Figure 1 Schematic representation of the human ASS gene and the ASS-EGFP transgene. (A) Structure of the human ASS gene. Human
ASS gene composes of 16 exons with the initiation codon (ATG) residing in exon 3 and the termination codon (TGA) in exon 16. There are two
poly(A) signals, pA1 and pA2, residing in exon 16 to produce ASS mRNA of 1.7 kb and 2.7 kb. UTR: untranslated region. (B) Structure of the Tg(ASS-Ex3-
EGFP) transgene. The EGFP coding sequence is inserted right after the initiation codon of the ASS gene. Transcription initiated from the ASS promoter
is terminated by a SV40 poly(A) signal, pAsv, residing immediate downstream of the EGFP gene. EGFP but not ASS protein is produced from this
transgene. (C) Structure of the Tg(ASS-Ex16-EGFP) transgene. EGFP is inserted in exon 16 between the termination codon and pA1 of the ASS gene.
Depending on which poly(A) signal is used, bicistronic mRNAs of 3.1 kb and 4.1 kb are produced. A sequence of IRES (internal ribosome entrance site)
is inserted in front of EGFP to facilitate EGFP protein translation. Both ASS and EGFP proteins are produced from this transgene.
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DAPI (4′,6-diamidino-2-phenylindole) (Roche Applied
Science, Indianapolis, IN). For immunohistochemical
studies, tissues fixed in buffered paraformaldehyde and
embedded in paraffin were deparaffinized, hydrated in
graded ethanol, and heated in 10 mM sodium citrate
(pH 6.0) plus 0.1% NP-40 by microwave oven to re-
trieve the antigens. The remaining activity of endogen-
ous peroxidase activity was quenched with hydrogen
peroxide. After blocking, the slides were incubated with
a primary antibody of GFP (1:100 dilution, anti-GFP,
rabbit polyclonal antibody) (Chemicon, Billerica, MA)
or 1:100 dilution of a mouse monoclonal anti-ASS anti-
body (BD Biosciences, San Jose, CA) overnight at 4°C.
Subsequently, the slides were incubated with the bio-
tinylated secondary antibody and streptavidin conjugated-
HRP (horseradish peroxidase). The HRP was then
visualized by the application of substrate chromogen
DAB (diaminobenzidine) (Dako, Glostrup, Denmark)to give brown color where the slides were counter-
stained with hematoxylin.
RNA isolation and S1 nuclease mapping analysis
For total RNA isolation, tissue was first grinded to
powder cooled in liquid nitrogen. The frozen powder
was transferred to a MagNA Lyser tube (Roche Ap-
plied Science, Indianapolis, IN) filled with 1 ml TRIzol
(Invitrogen, Carlsbad, CA) and homogenized immedi-
ately by MagNA Lyser homogenizer (Roche Applied
Science, Indianapolis, IN). The supernatant was used in
RNA isolation following manufacturer’s instructions. For
S1 nuclease mapping, appropriate restriction enzyme-
digested DNA fragment was labeled at the 5’-end with
[γ-32P] ATP and T4 polynucleotide kinase [11]. The la-
beled DNA probe was hybridized to total RNAs pre-
pared from the mouse tissues. The DNA-RNA hybrids
that resisted to S1 nuclease digestion were electropho-
resed through a 4% polyacrylamide gel containing 7 M
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raphy or by a phosphorimager (Molecular Dynamics,
Sunnyvale, CA).
Results and discussion
ASS-EGFP expression during liver development
ASS expression in the liver has been shown to be develop-
mentally regulated. In the rat, Ass mRNA is first detected
in E15.5 fetal stage and increases continuously to neonatal
stage [12]. To visualize ASS expression during liver devel-
opment and to study whether post-transcriptional regula-
tion is involved, studies were taken using transgenic mice
Tg(ASS-Ex3-EGFP) 3GTsu and Tg(ASS-Ex3-EGFP) 3JTsu,
abbreviated as 3G and 3J, that carry, respectively, 30 and 2
copies of the transcription reporter and Tg(ASS-Ex16-
EGFP) 16ETsu and Tg(ASS-Ex16-EGFP) 16FTsu, abbrevi-
ated as 16E and 16 F, that carry, respectively, 10 and 5
copies of the transcription/post-transcription couple re-
porter. EGFP fluorescence of liver tissues taken from fe-
tuses at E14.5 to E17.5 (some to E18.5), 1 to 7 days and 2,
3 and 4 weeks after birth were examined directly under a
fluorescence dissecting microscope (Figure 2A). Images
were captured with 1.25-fold magnification for samples at
stages E14.5 to D7 and 0.7-fold for those at stages W1 to
W4. Images D7 and W1 in Figure 2A were taken from an
identical sample. The difference in their fluorescence
brightness is mainly due to the fact that the image bright-
ness is inversely proportional to the square of the trans-
verse magnification [13]. Moreover, image was captured
using a constant 4-second exposure time except in 3G line
which was reduced to 1 second due to strong EGFP sig-
nals. At E14.5 stage, EGFP fluorescence was weak ex-
cept in the 3G line (Figure 2A, bottom panel, exposed
for 4 seconds). Considerable enhancement of EGFP sig-
nal could be seen at day 1 and increased gradually to
4 weeks. Similar patterns of expression could also be
seen in the 16E and 16 F lines, except that the signals
were weaker (Figure 2A). Variations in EGFP fluores-
cence among mouse littermates were also observed. For
example, the EGFP fluorescence was relatively strong in
a liver sample of 16 F (Figure 2A, 16 F D2).
Zonation of metabolic pathways is believed to be a
mechanism leading to efficient use of precursor pools
and energy in an organism [14]. In the rodent, urea cycle
enzymes in the liver show zonation distribution, i.e., they
are present predominantly in the periportal hepatocytes
and declining gradually toward the pericentral hepato-
cytes. Such a distribution pattern occurs not only at the
protein level but also in the mRNAs of these enzymes
[14]. To study whether zonation can be visualized by
EGFP fluorescence, frozen sections of the liver were
examined. Similar EGFP zonation pattern could clearly
be seen between transgenic lines carrying the transcription
reporter, i.e., 3G and 3J, and the transcription/post-transcription couple reporter, i.e., 16E and 16 F (Figure 2B).
In the rodent, Ass RNA zonation has been shown to
appear 2 days before birth [14]. In agreement, zon-
ation gradually became apparent at E17.5 and E18.5
(Figure 2C, 3J line) where near-homogeneous EGFP
fluorescence distribution was found at E14.5 and E15.5
stages (Figure 2C, 3G line). However, human ASS has
been reported to be present in all hepatocytes with no
marked zonation [15]. The ASS-EGFP transgene in this
study is of human origin, and yet EGFP expression mani-
fested zonation pattern similar to that of the rodent Ass.
Apparently, establishment of zonation pattern is made at
transcription initiation and such regulation may be influ-
enced by cellular environment. Thus, human ASS gene
when in the rodent background follows the expression
pattern of the rodent.
ASS-EGFP expression during kidney development
Kidney is the major organ of arginine production in
adult where ASS is the rate-limiting step in the conver-
sion of citrulline to arginine [1]. Similar to the liver,
EGFP fluorescence in the kidney was weak at E14.5 stage
except that of the 3G line (Figure 3A, bottom panel).
Marked enhancement of EGFP expression was observed
during neonatal (Figure 3A, D1 stage). The ASS protein
and mRNA have been shown to localize exclusively in
the proximal tubules of renal cortex [16]. Indeed, in our
transgenic mice, EGFP fluorescence was mainly found in
the renal cortex area (Figure 3B). Renal cortex can be
divided into alternate regions of cortical labyrinth and
the medullary rays [17]. EGFP signal appeared in cor-
tical labyrinth (Figure 3C, CL) and not in the medullary
rays (Figure 3C, MR). The cortical labyrinth consists of
glomeruli and convoluted tubules where EGFP signal
appeared in the convoluted tubules and not in the
glomeruli (Figure 3C, lower panel). To examine the kidney
structure in detail, immunohistochemical studies using
EGFP and ASS antibodies were performed (Figure 3D).
Signals were found in the proximal convoluted tubules
and the parietal epithelium but were absent in the glom-
eruli and the distal convoluted tubules when analyzed by
either EGFP or ASS antibodies. Therefore, the ASS-EGFP
transgene is faithfully expressed as an authentic ASS
gene. On the other hand, to study the EGFP expression
pattern during kidney development, kidney frozen sec-
tions in various developmental stages were examined
(Figure 3E). At E14.5 and E15.5 stages, EGFP fluores-
cence was found to distribute rather homogenously in
the entire kidney (Figure 3E, 3G line). Fluorescence in
the structure of the renal pelvis was also visible. The
nephrogenic zone can be divided into the cortex and
medulla in mouse kidney at E15.5 [18]. During perinatal
stage, EGFP fluorescence was found primarily in the
cortex although weak signals were visible in the collecting
(C) 3G
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Figure 2 EGFP expression during liver development in the transgenic mice. (A) Observing EGFP fluorescence under a fluorescence
dissecting microscope. Liver samples taken from fetal stages (E14.5-E17.5), 1 day to 7 day (D1-D7) and 1 to 4 week (1 W-4 W) after birth were
examined directly under a fluorescence dissecting microscope. 3G, 3J, 16E, 16 F, WT represent Tg(ASS-Ex3-EGFP) 3GTsu, Tg(ASS-Ex3-EGFP) 3JTsu, Tg
(ASS-Ex16-EGFP) 16ETsu, Tg(ASS-Ex16-EGFP) 16FTsu and wild-type mouse lines, respectively. Images were taken with an exposure time of 4 seconds
except for 3G line with 1 second. Images in the bottom panel of fetal stage of 3G line were taken with exposure time of 4 seconds. Images were
captured with magnification of 1.25-fold for samples at E14.5 to D7 and 0.7-fold for W1 to W4. Images D7 and W1 were taken from an identical sample.
Each grid is 1 mm. (B) Comparison of liver zonation patterns among mouse lines. Liver frozen sections taken from 1- to 4-week transgenic lines and
wild type were examined by fluorescence microscopy. Exposure time of the images was 50 ms except for 3G of 1 ms. Scale bar, 200 μm. (C) Study
of EGFP fluorescence pattern in cryosections. Mouse liver sections were fixed and embedded in OCT compound. Serial frozen sections were
examined by fluorescence microscopy. Left bottom panel was sections stained by DAPI. The liver stage and mouse line employed are as
indicated. Scale bar, 200 μm.
Shiue et al. Journal of Biomedical Science 2014, 21:42 Page 5 of 13
http://www.jbiomedsci.com/content/21/1/42duct of the medulla (Figure 3E, stages E16.5-D2). At later
stages, fluorescence was essentially seen in the cortex
where areas of fluorescence increased. Thus, ASS-EGFP
expression recaptures the feature of Ass gene in the mouse
kidney [16].
ASS-EGFP expression during intestine development
The small intestine is the major organ in arginine syn-
thesis during the perinatal stage of development, butgradually shifts to citrulline production. Citrulline gener-
ated is then taken up by the kidney where it is converted
to arginine. The collaboration between the intestine and
the kidney in arginine synthesis becomes established
postnatally, constituting the intestinal-renal axis [19]. To
study whether EGFP fluorescence in the small intestine
in the ASS-EGFP transgenic mice can reproduce such
regulation, EGFP fluorescence in the digestion system
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Figure 3 (See legend on next page.)
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Figure 3 EGFP expression during kidney development in the transgenic mice. (A) Study of EGFP fluorescence by fluorescence dissecting
microscopy. Conditions were as described in the legends of Figure 2A. (B) Comparison of fluorescence patterns of the kidney among the mouse
lines. Kidney frozen sections taken from 1- to 4-week transgenic mice and non-Tg controls were examined by fluorescence microscopy. Exposure time
was 50 ms except for 3G of 1 ms. Scale bar, 200 μm. (C) Localization of EGFP fluorescence. Frozen sections of kidneys from 1-week old transgenic
mouse 3J were examined by fluorescence microscopy. A region of enlarged image was selected (white box) and shown in the lower panel. In each
panel: left, fluorescence image; middle, DAPI staining; right, fluorescence image merged with DAPI staining. Particular regions are distinguished by
dotted lines: C: cortex; M: medulla; CL: cortical labyrinth; MR: medullary ray. The glomerulus is circled in yellow. (D) Immunohistochemical localization
of EGFP and ASS. Paraffin sections of the kidney from 4 week-old transgenic mouse 3G were incubated with an EGFP antibody (upper panel) or ASS
antibody (lower panel). The slides were incubated with the biotinylated secondary antibody coupled with streptavidin conjugated-HRP and was
visualized by the application of chromogen DAB to produce brown color when the slides were counterstained with hematoxylin. PCT: proximal
convoluted tubule; DCT: distal convoluted tubule; G: glomerulus; PE: parietal epithelium. Scale bar, 200 μm. (E) EGFP fluorescence patterns during
kidney development of the transgenic mice. Mouse kidney was fixed and embedded in OCT compound. Serial frozen sections were examined by
fluorescence microscopy. In each panel: top, EGFP fluorescence image, middle, DAPI staining, bottom, EGFP fluorescence image merged with DAPI
staining. The developmental stages and mouse lines employed are as indicated. Areas of the cortex (C) and the medulla (M) are distinguished by
dotted lines. Scale bar, 200 μm.
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ney, the EGFP signals in the intestine were clearly visible
in the fetal stages (Figure 4A). The signals persisted in to
the perinatal stage but decreased gradually around the
time of weaning (Figure 4A). It is noted that substantial
auto-fluorescence could be seen in organs of a wild-type
mouse, especially in the stomach (Figure 4A, WT). Such
signals in part originated from the food intake (data not
shown). On the other hand, De Jonge et al. [20] have
studied temporal expression of urea cycle enzymes in
the rat small intestine during perinatal development. By
northern blot analysis and in situ hybridization, they
found in the fetal stage that the proximal loops of the in-
testine expressed the Ass mRNAs at higher concentra-
tions than the more distal loops. In agreement, frozen
sections of the transgenic fetuses at E14.5 or E15.5 showed
pronounced EGFP signals in the proximal loops of the in-
testine in the region closer to the liver (Figure 4B, white
arrow) while only weak signals were seen in the distal
parts of the intestine (Figure 4B, red arrow). In addition,
EGFP signals were clearly seen in the enteric neurons of
the myenteric ganglion (Figure 4B, MG). Thus, EGFP sig-
nals in the small intestine of the ASS-EGFP transgenic
mice appear to recapture the temporospatial expression of
rodent Ass.
Expression profiling of EGFP and Ass mRNAs in the liver,
kidney and intestine by S1 nuclease mapping
Studies described above show that EGFP fluorescence in
the liver, kidney and intestine examined by fluorescence
microscopy either directly or after cryosectioning is use-
ful to study ASS expression. In such analyses, no gross
disparity in EGFP expression was found between mouse
lines of Tg(ASS-Ex3-EGFP) Tsu and Tg(ASS-Ex16-EGFP)
Tsu. To be quantitative, EGFP mRNA profiles of the
liver, kidney and intestine were examined by S1 nuclease
mapping. In addition, the ASS-EGFP transgene is of hu-
man origin. To examine whether species-specific expres-
sion pattern existed, comparison was also made betweenexpression profiles of the EGFP mRNA and the en-
dogenous mouse Ass mRNA. Abundances of EGFP and
Ass mRNAs from the liver, kidney and intestine in different
developmental stages were analyzed and quantified by S1
nuclease mapping; where levels of EGFP and Ass mRNAs
were first normalized to the mRNA level of Gapdh, a
house keeping gene glyceraldehyde-3-phosphate dehydro-
genase. The mRNA structures of EGFP, Ass and Gapdh,
their 5′-end labeled cDNA probes and the expected sizes
of protected fragment are depicted in Figure 5A. The
probes are designed such that the size of protected frag-
ment by respective probes could easily be distinguished by
denatured polyacrylamide gel electrophoresis. RNAs were
hybridized in reaction containing individually end-labeled
cDNA probes of EGFP, mouse Ass and mouse Gapdh.
DNA-RNA duplexes were analyzed by electrophoresis after
removing unhybridized RNA and single-stranded probes
by S1 nuclease. It is worth noting that in this analysis, the
human ASS mRNA expressed from the Tg(ASS-Ex16-
EGFP) Tsu line cannot be detected by the mouse Ass
probe. Moreover, to study RNA expression of a particular
organ, same batch of the labeled probes was used to avoid
signal variations due to differences in probe specific activ-
ities. Representative images acquired by the phosphorima-
ger on the analysis of liver, kidney and intestinal RNAs and
the expression profiles of EGFP and Ass mRNAs are pre-
sented (Figures 5, 6 and 7).
Analysis of liver RNA from fetal E14.5 stage to 4 week
after birth, EGFP mRNA level was found to increase
progressively during the development (Figure 5B). Sig-
nificant variations in EGFP mRNA abundances among
mouse littermates were found. Such variations were also
noted when EGFP fluorescence of a particular organ was
examined directly (Figures 2A, 3, 4A). To study whether
EGFP expression profile differs between Tg(ASS-Ex3-
EGFP) Tsu and Tg(ASS-Ex16-EGFP) Tsu lines during liver
development, relative abundances of EGFP mRNAs was
determined (Figure 5C, upper panel). The EGFP mRNA
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Figure 4 EGFP expression during intestine development in the transgenic mice. (A) Study of EGFP fluorescence by fluorescence dissecting
microscopy. At stage E14.5 to 2 week, structures including the stomach, small and large intestines were included and examined. Due to the size,
at the 3-week stage only stomach and small intestine and at 4 weeks small intestine alone were examined. Conditions were as described in the
legends to Figure 2A. (B) Expression of EGFP during small intestine development. Fetuses at E14.5 stage of 3G line (left panel) and E15.5 stage of
16E line (right panel) were embedded in OCT compound. Frozen sections were examined by fluorescence microscopy. White arrow marked the
proximal intestine and red arrow marked the distal intestine. MG: myenteric ganglion. Scale bar, 500 μm.
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(Figure 5C, upper panel), suggesting that developmental
ASS expression in the liver is mainly controlled at tran-
scription initiation. If the novel post-transcriptional regu-
lation affecting ASS nuclear precursor RNA stability
similar to that in canavanine-resistant variants occurred in
the Tg(ASS-Ex16-EGFP) Tsu line [7], one would expect
the EGFP mRNA level in the Tg(ASS-Ex16-EGFP) Tsu line
to increase by one to two orders of magnitude from current
levels. However, whether any subtle post-transcriptional
regulation on ASS mRNA has taken place would require
further studies. Nevertheless, both the 1.7- and 2.7-kb ASS
mRNA species are highly stable with a half-life of approxi-
mately 15–20 h [21]. It is noted that among the organs ex-
amined, EGFP fluorescence in the Tg(ASS-Ex16-EGFP) Tsu
line was generally weaker yet considerably high levels of
EGFP mRNA could be detected. It is likely that EGFP in
the Tg(ASS-Ex16-EGFP) Tsu line, which is the downstreamcistron, is translated by IRES mechanism which may be less
efficient comparing to cap-dependent translation of EGFP
in the Tg(ASS-Ex3-EGFP) Tsu line.
In rodents, Ass gene expression, assayed by RNA or by
activities, is reported to increase progressively towards
birth reaching about 50% of adult liver value [1]. In con-
trast, in human fetuses, ASS activities reached 90% of
the adult value at 36 weeks of gestation [22]. Our study
showed that the EGFP mRNA abundances at birth were
less than 40% of the adult values (Figure 5C, upper
panel). Thus, EGFP mRNA profile during liver develop-
ment is similar to that of mouse Ass mRNA, suggesting
that the human ASS gene in the mouse background fol-
lows the mouse Ass developmental pattern. Similar con-
clusion has been obtained as evidenced by liver zonation
distribution of EGFP fluorescence (Figure 2B). Thus, the
human ASS gene in the mouse genetic background fol-






































































Protected size: 715 nt
Probe: 3873 bp
Protected size: 916 nt
5’- -3’Mouse Gapdh mRNA: 1.2 kb
Probe: 3552 bp





Figure 5 Determination of relative abundances of EGFP and mouse Ass mRNAs during liver development by S1 nuclease mapping.
(A) Strategy of S1 nuclease mapping. RNA structures, DNA probes and the predicted protected probe size after S1 nuclease digestion are
depicted. Stars indicate 32P 5'-end labels; wavy line at one end of the labeled probe indicates vector sequences that distinguish a re-annealed
probe from a probe that was protected by hybridization to RNA. (B) Phosphorimage analysis of the protected fragments from S1 nuclease mapping.
RNAs isolated from various stages of liver development (indicated on top) were hybridized to the 5' end-labeled probes and the DNA-RNA hybrids
that resisted S1 nuclease digestion were electrophoresed through a 4% polyacrylamide gel containing 7 M urea. Gel was dried and analyzed by a
phosphorimager. The protected fragments corresponding to mRNAs of mouse Ass, EGFP transgene and mouse Gapdh are marked on the right.
Mouse lines from which RNAs were obtained are indicated on the left. (C) EGFP and Ass mRNA profiles during liver development. The intensities of
hybridization signals of EGFP, Ass and Gapdh mRNAs were quantified by a phosphorimager where the levels of EGFP and Ass mRNAs were normalized
to the level of the Gapdh mRNA. Relative abundances of EGFP mRNA (upper panel) and Ass mRNA (lower panel) during liver development are plotted
by taking the stage of the highest level as 100%. Standard deviation (solid line) is shown if analysis was performed at least 3 times. If performed twice,
average with interval of two values is shown (dotted line).
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http://www.jbiomedsci.com/content/21/1/42surprising since the ASS gene during liver development
is known to subject to both hormonal and nutritional
regulation [1,2]. Therefore, cellular environment plays
important role in ASS expression. The results indicate
that the cis-elements required for ASS expression during
liver development are similar between the human and
the mouse, and the ASS-EGFP transgene carries suffi-
cient elements to execute such regulation.
To study whether the transgene expression may affect
endogenous Ass gene expression, levels of Ass mRNA
were compared between the 3G and 3J lines of Tg(ASS-Ex3-EGFP) Tsu, which carry 30 and 2 copies of transgene,
respectively. Indeed, a significantly higher level of EGFP
mRNA was found in the 3G line compared to that of the
3J line, yet comparable abundance of Ass mRNA was de-
tected among the transgenic lines 3G and 3J and that of
the wild-type mouse (Figure 5C, lower panel). Similar re-
sults were found in the analysis of the Tg(ASS-Ex16-EGFP)
Tsu line (Figure 5C, lower panel 16E and 16 F). Therefore,
even in the presence of high copies of the transgene, no
apparent sequestration of transcription factors to affect












































Figure 6 Determination of relative abundances of EGFP and mouse Ass mRNAs during kidney development by S1 nuclease mapping.
(A) Phosphorimage analysis of the protected fragments from S1 nuclease mapping of kidney RNA. Condition was as described in the legends to
Figure 5. (B) EGFP and Ass mRNA profiles during kidney development. The intensities of hybridization signals of EGFP, Ass and Gapdh mRNAs
were quantified by a phosphorimager where the levels of EGFP and Ass mRNAs were normalized to the level of the Gapdh mRNA. Relative
abundances of EGFP mRNA (upper panel) and Ass mRNA (lower panel) during kidney development are plotted by taking the stage of the highest
level as 100%. Standard deviation (solid line) is shown if analysis was performed at least 3 times. If performed twice, average with interval of two
values is shown (dotted line).
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http://www.jbiomedsci.com/content/21/1/42Approach similar to that of the liver was taken to
study EGFP mRNA expression during kidney develop-
ment (Figure 6). However, due to limit amounts of sam-
ple in fetal E14.5 and E15.5 stages, analysis started at
fetus E16.5 stage. Representative images of RNA analysis
by S1 nuclease mapping are shown in Figure 6A. The
EGFP expression profile was similar between the Tg
(ASS-Ex3-EGFP) Tsu and Tg(ASS-Ex16-EGFP) Tsu lines
(Figure 6B, upper panel), suggesting ASS expression dur-
ing kidney development is controlled mainly at the tran-
scription level. By comparing Ass mRNA levels between
wild-type and transgenic lines, one concludes that ex-
pression of the transgene does not interfere with expression
of the endogenous Ass gene during kidney development in
the mouse (Figure 6B, lower panel).
To study EGFP mRNA expression profiles in the intes-
tine, RNA of the digestion system including stomach to
rectum at the fetal stage was isolated. After birth, only
RNA from the small intestine was analyzed. BecauseEGFP fluorescence intensity was found to vary among
different sections of the small intestine (data not shown),
to avoid complication, the entire small intestine was col-
lected and used for RNA isolation. In this study, we
again showed that EGFP mRNA abundance during in-
testine development is mainly controlled at the tran-
scription initiation and expression of the transgene did
not interfere with endogenous Ass expression (Figure 7).
Interestingly, although there were similarities between
the expression profiles of EGFP and Ass mRNAs, some
differences did exist (Figure 7B). For example, in con-
trast to EGFP mRNA which showed smooth increases in
its abundance perinatally, a rather sharp increase in Ass
mRNA abundance at E17.5 stage was observed (Figure 7B).
Moreover, the Ass mRNA levels declined sharply at
3 weeks of age, but substantial EGFP mRNA could be de-
tected at this stage in both Tg(ASS-Ex3-EGFP) Tsu or Tg
(ASS-Ex16-EGFP) Tsu lines (Figure 7B). In this regard, a












































Figure 7 Determination of relative abundances of EGFP and mouse Ass mRNAs during intestine development by S1 nuclease mapping.
(A) Phosphorimage analysis of the protected fragments from S1 nuclease mapping of intestine RNA. Condition was as described in the legends
to Figure 5. (B) EGFP and Ass mRNA profiles during intestine development. The intensities of hybridization signals of EGFP, Ass and Gapdh mRNAs
were quantified by a phosphorimager where the levels of EGFP and Ass mRNAs were normalized to the level of the Gapdh mRNA. Relative
abundances of EGFP mRNA (upper panel) and Ass mRNA (lower panel) during kidney development are plotted by taking the stage of the highest
level as 100%. Standard deviation (solid line) is shown if analysis was performed at least 3 times. If performed twice, average with interval of two
values is shown (dotted line).
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http://www.jbiomedsci.com/content/21/1/42developing rat small intestine found that mRNA levels of
all genes in arginine metabolism were highest during the
suckling period where Ass mRNAs declined to hardly de-
tectable levels in the second postnatal week [20]. On the
other hand, in piglets, net synthesis of arginine declines
more gradually in the small intestine and is still present at
7 weeks of age [23]. The perinatal human intestine resem-
bles that of piglets in that ASS activities are highest during
the suckling period and declines to low levels around
weaning and then rises again [24]. Thus, in contrast to
mouse Ass mRNA that disappears completely at 3 week,
the EGFP mRNA expression profile of the transgenic mice
resembles human ASS in that substantial levels of EGFP
mRNA could still be detected at 8 weeks of age (Figure 7).
Apparently, ASS gene in humans and pigs has specific cis-
element(s) which differ from those of the rodent in
regulating ASS expression in the small intestine. By com-
parison of the upstream ASS gene sequences in human,
pig and mouse, such cis-element(s) may be deduced.Using transgenic mouse system, we show in this study
that developmental- and tissue-specific ASS expression
of liver, kidney and intestine is mainly controlled at tran-
scription initiation. This is not surprising since tran-
scription initiation, the first step of gene regulation, is
the most important mechanism to determine whether or
not genes are expressed and then, how much of encoded
mRNAs are produced. On the other hand, the novel
post-transcriptional regulation identified in canavanine-
resistant variants may be so genetically programmed in
particular cell types to meet immediately the demand for
high ASS activity. Our preliminary study indicates such
regulation may occur during mouse fetal brain develop-
ment (T Su, unpublished data). The region of the brain
involved is currently under characterization. On the
other hand, the ASS gene in this transgenic mouse sys-
tem is of human origin. How would the transcriptional
programs of human gene follow in mouse genetic back-
ground? In this regard, Wilson et al., [25] have initiated
Shiue et al. Journal of Biomedical Science 2014, 21:42 Page 12 of 13
http://www.jbiomedsci.com/content/21/1/42an important study by taken a mouse model of Down
syndrome in which mouse cells contain a copy of human
chromosome 21. They concluded that genetic sequence is
largely responsible for directing transcriptional programs
in homologous tissues. Others such as interspecies differ-
ences in epigenetic machinery, cellular environment, and
transcription factors themselves play secondary roles. Our
study shows that developmental program of ASS-EGFP
transgene in liver is similar to rodent, suggesting genetic
elements determining liver development are comparable
between human and rodent. Thus, cellular environments
play important role in shaping ASS-EGFP transcriptional
program during liver development. On the other hand,
the time course of EGFP expression in small intestine re-
sembles that of human ASS gene, suggesting the presence
of particular genetic sequence(s) in ASS gene that dictates
human intestine development.
Conclusions
We demonstrate that this transgenic mouse system is
ideal for annotation of temporal and spatial expression
profiles of the ASS gene. In particular, the Tg(ASS-Ex3-
EGFP) 3GTsu line, containing 30 copies of the transgene,
generates strong EGFP signals, and is, thus, useful in re-
vealing weak expression. It is conceivable that a compre-
hensive knowledge of cell types expressing ASS may
provide insights into the function. Such knowledge should
facilitate investigation of the role of ASS in conditions of
physiological and disease states, especially when ASS
mRNA or protein are found not to be expressed in many
tumours including hepatocellular carcinoma (HCC), mel-
anoma, some mesotheliomas, renal cell cancers, sarcomas
and lymphomas [26]. As a result, arginine deprivation
employing the pegylated form of arginine deiminase
(ADI-PEG20) as a targeted therapy is currently in clinical
trials for patients with HCC and melanoma [26]. In this
respect, feature of down-regulated expression of ASS in
HCC has been recaptured in our ASS-EGFP transgenic
mouse model (manuscript in preparation). Thus, ques-
tions such as physiological or pathophysiological response
of ASS expression stimulated by a variety of signals may
be tackled using this system.
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